Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.
OncoMed Pharmaceuticals announced last week that the US Patent and Trademark Office granted its first US patent for technology to identify mAbs (monoclonal antibodies).
Big Pharma interest in antibody drug conjugates (ADC) hit another high this week with Roche ,Novartis and AstraZeneca each announcing investments that boost their ability to develop and manufacture these small-molecule monoclonal antibody (mAb) drug...
GlaxSmithKline will wait to ramp up manufacturing capacity of its promising malaria vaccine until after it makes its way through the regulatory process.
Biotech developer Regeneron is investing as much as $300m in its New York manufacturing plants and for a new site in Ireland as part of preparations for a potential new blockbuster monoclonal antibody that treats high cholesterol.
With in-house production and manufacturing capacity, as well as a deal with Merck Serono, India-based generics giant Dr. Reddy’s is looking to bring as many as four biosimilars to the EU market by 2019.
Biocatalyst and microbial strain developer Brain AG was recognised for furthering industrial use of biotechnology in a ceremony at the Biotechnica trade show in Hanover, Germany yesterday.
Ablynx and Merck Serono expanded their relationship for a fourth time – this time in a four-year deal worth about $34m (€25m), including an initial payment of $15.5m (€11.5m).
MIT engineers have developed a new nanoparticle that can protect a vaccine long enough to generate a strong immune response on mucosal surfaces far from the vaccination site.
The US Department of Health and Human Services (HHS) says it is buying cell lines to manufacture anthrax antitoxins on top of its $196m (€145m) deal with GlaxoSmithKline to stockpile Raxibacumab.
Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.
A new platform to help biopharma companies discover antibodies is also helping them go after more difficult targets and earn more collaborations with top biopharma companies.
The US Defense Advanced Research Projects Agency (DARPA) has awarded MIT’s Biomanufacturing Research Program (BioMAN) a $10.4 million grant from to develop devices and techniques to more rapidly produce biologics.
Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.
Roche has agreed to research, develop and commercialize Inovio Pharmaceuticals' vaccine delivery tech as well as its multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.
The US FDA approval of the new quadrivalent flu vaccine in June has not quite given manufacturers enough time to meet demand expectations, as production time can take up to about six months.
A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.
Biopharma researchers will be able to use a new technology to explore biomarkers and pathways with more sensitivity and precision to create new diagnostics and improved oncology, neurology, cardiology and other therapies.
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
Eli Lilly has extended its collaboration with Immunogen to use its antibody-drug conjugate (ADC) technology for development of a specific antigen target.
Rani Therapeutics announced Wednesday that it has closed its Series B round of funding after pulling in more than $10m from Google Ventures, InCube Ventures and VentureHealth, a healthcare crowdfunding portal.
Investors on Tuesday seemed a little less sure of biopharma behemoth Amgen’s decision to purchase cancer specialist Onyx for more than $10B over the weekend.
The new UK biomanufacturing hub will help BioPharmas cut costs and let those developing novel biodrugs assess manufacturability according to the Centre for Process Innovation (CPI).
Stemcell Technologies will use BioLife Solutions’ cryopreservation media to ship its new range of stem cell based products under an expanded agreement.
GlaxoSmithKline is gambling $50M on a venture capital fund that will invest in 20 projects that pioneer bioelectric drugs and technologies that aim to target individual nerve fibres or specific brain circuits to treat an array of conditions.
New flexible vaccine technology could pave the way for pneumococcal, TB and staphylococcus aureus vaccines that are cheaper to produce and more effective.
PharmAthene and Theraclone Sciences announced plans to merge and continue the joint development of monoclonal antibodies (mAbs) and vaccines on the verge of progressing to Phase II and III trials.
The US National Institutes of Health (NIH) announced this week that the famous HeLa genomic sequence data will continue to be available for scientists worldwide, though they will have to apply for access to the data.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
GlaxoSmithKline says MAbs (monoclonal antibodies) will play an important part in its future pipeline as it licenses and internalizes a discovery tech platform from Adimab.
Making better CHO cell lines for biomanufacturing may soon be a more precise task according to the team behind the draft Chinese hamster genome published last week.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
Harbour Antibodies has received a double boost this week raising $3.3m (€2.5m) for its transgenic H2L2 mice technology and adding Pfizer to its list of clients.
Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.
